Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.40 |
| ▸ | HTR3A | P46098 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3756715 | 0.98 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL1782928 | 0.90 | FURIN (0.35) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL504169 | 0.82 | HTR3A (0.52) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL503793 | 0.82 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL3247883 | 0.78 | GRIN2D (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL244511 | 0.76 | MAPT (0.40) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL2899831 | 0.72 | CYP2A6 (0.39) | CHRNA7HTR3A | |
| Fumaric Acid SCHEMBL503831 | 0.71 | CHRNA1 (0.34) | CHRNA7HTR3AKCNH2 | |
| Fumaric Acid SCHEMBL504343 | 0.71 | HTR3A (0.43) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL2901108 | 0.71 | CHRNA7 (0.40) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305108-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-12-02 | — | — | US | claimed |
| US-20090197872-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-08-06 | — | — | US | claimed |
| EP-2041134-A1 | NOVEL 1,4-DIAZA-BICYCLOÝ3.2.2¨NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-04-01 | — | — | EP | claimed |
| WO-2007138039-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | claimed |
| EP-2209783-B1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2016-03-16 | — | — | EP | disclosed |
| US-8343960-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use | NEUROSEARCH A/S (DK) | 2013-01-01 | — | — | US | disclosed |
| US-8148365-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use | NEUROSEARCH A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20120004215-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2389380-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2011-11-30 | — | — | EP | disclosed |
| US-8041176-B2 | Cable exit trough with cover | ADC TELECOMMUNICATIONS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2029595-B1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE | NEUROSEARCH AS (DK) | 2011-09-21 | — | — | EP | disclosed |
| US-7935695-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands | NEUROSEARCH A/S (DK) | 2011-05-03 | — | — | US | disclosed |
| WO-2009062989-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-05-22 | — | — | WO | disclosed |
| EP-2049538-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2009-04-22 | — | — | EP | disclosed |
| EP-2041134-A1 | NOVEL 1,4-DIAZA-BICYCLOÝ3.2.2¨NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-04-01 | — | — | EP | disclosed |
| EP-2029595-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE | NeuroSearch A/S (DK) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009024517-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL HETEROARYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2009-02-26 | — | — | WO | disclosed |
| WO-2007138040-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138039-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138041-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305108-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | CHRNA6, CHRNA5, CHRNA4 | CHRNA7 7/4885HTR3A 89/4885KCNH2 1305/4885 |
| US-20090197872-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE | CHRNA2, CHRNA6, CHRNA3 | CHRNA7 7/4885HTR3A 82/4885KCNH2 869/4885 |
| US-20120004215-A1 | N-OXIDES OF DIAZABICYCLONONYL PYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | CHRNA5, CHRNA6, CHRNA10 | CHRNA7 5/4885HTR3A 176/4885KCNH2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.